EGFR and non-small cell lung carcinoma: Mechanistic studies demonstrated that TGF-β1 exposure led to significant downregulation of SYK and upregulation of FRA1 along with a shift to a mesenchymal cell state in MET-amplified and EGFR-mutant NSCLC cell lines, and these effects were reversed by a TGF-β1 inhibitor (Fig. 3g and Supplementary Fig. S7a).